Yu-Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yu-Jie Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Binghua Jiao
Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China
1 shared publication - Xiao-Yu Liu
Naval Medical Center of PLA, Naval Medical University, Shanghai 200433, China
1 shared publication - Xiaoling Lu
College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China
1 shared publication - Xin Cao
Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China
1 shared publication - Yuyan Li
Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
1 shared publication
Latest Publications
- Open Access
- 13 January 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (1) , 18
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
Antibody–drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past several years. The development of highly specific antibodies, novel marine toxins’ applications, and innovative linker technologies all accelerate the rapid R&D of ADCs. Meanwhile, some challenges remain to be solved for future ADCs. For instance, varieties of site-specific conjugation have been proposed for solving the inhomogeneity of DARs (Drug Antibody Ratios). In this review, the usages of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs in the past decade are summarized. Representative ADCs with marine cytotoxins in the pipeline are introduced and characterized with their new features, while perspective comments for future ADCs are proposed.
- 13 January 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (1) , 18
Open AccessMarine Antibody–Drug Conjugates: Design Strategies and Research Progress
Antibody–drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past several years. The development of highly specific antibodies, novel marine toxins’ applications, and innovative linker technologies all accelerate the rapid R&D of ADCs. Meanwhile, some challenges remain to be solved for future ADCs. For instance, varieties of site-specific conjugation have been proposed for solving the inhomogeneity of DARs (Drug Antibody Ratios). In this review, the usages of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs in the past decade are summarized. Representative ADCs with marine cytotoxins in the pipeline are introduced and characterized with their new features, while perspective comments for future ADCs are proposed.